Company intelligence / Profile preview

SevenScore

Ownership: Private
Development stage: Other

Overview

SevenScore was a pre-revenue biotechnology company that obtained assignment of a clinical licensing agreement for the CCR5 antagonist leronlimab from Vyera/CytoDyn but, based on public filings, did not itself advance products to late-stage clinical development and has effectively become inactive.[6][7]

Therapeutic areas: Infectious Diseases
Modalities: Monoclonal antibodyBiologic
Industry: Biotech

Partnerships

CytoDynVyera Pharmaceuticals

Beyond the preview

Go deeper on SevenScore.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SevenScore.

Explore the full profile